GB887872A - Improvements in or relating to pharmaceutical preparations - Google Patents

Improvements in or relating to pharmaceutical preparations

Info

Publication number
GB887872A
GB887872A GB15720/59A GB1572059A GB887872A GB 887872 A GB887872 A GB 887872A GB 15720/59 A GB15720/59 A GB 15720/59A GB 1572059 A GB1572059 A GB 1572059A GB 887872 A GB887872 A GB 887872A
Authority
GB
United Kingdom
Prior art keywords
soluble
water
toxic
polyethylene glycol
molecular weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB15720/59A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of GB887872A publication Critical patent/GB887872A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A pharmaceutical base suitable for shaping by extrusion comprises a solid polyethylene glycol of molecular weight from about 4,000 to about 6,000; a liquid polyethylene glycol soluble in the solid polyethylene glycol; a non-toxic, non-ionic solid oil-soluble surface-active agent; spermaceti; a non-toxic, non-ionic solid water-soluble surface-active agent; and a non-toxic, solid carrier mixture of which between about 80% and 90% by weight is water-soluble. Preferred oil-soluble surface-active agents are polyoxyethylene sorbitan mono- and tri-stearates. Water-soluble surface-active agents preferred have the formula HO(C2H4O) (C3H6O) (C2H4O)H with a polypropyleneoxy base molecular weight of about 1,750 and a total molecular weight of about 8,750. Also suitable are polyoxyethylene stearate and palmitate. In the carrier beta lactose, sucrose, dextrose, sodium chloride or sodium sulphate may form the water-soluble part and the balance may be starch with which methylcellulose, guar gum or purified wood cellulose may be mixed. A number of medicinal ingredients for mixing with the base are listed (see Group VI).ALSO:A pharmaceutical preparation contains a medicament and a base suitable for shaping by extrusion-moulding comprising a polyethylene glycol having a molecular weight between about 4000 and about 6000; a liquid polyethylene glycol soluble in the solid polyethylene glycol; a non-toxic non-ionic solid oil-soluble surface-active agent; spermaceti; a non-toxic non-ionic solid water-soluble surface-active agent; and a non-toxic solid carrier mixture of which between about 80% and about 90% is water-soluble. Preferred oil-soluble surface-active agents are polyoxyethylene mono- and di-stearates. Water-soluble surface-active agents preferred have the formula HO(C2H4O)(C3H6O)(C2H4O)H with a polypropylene oxy base molecular weight of about 1750 and a total molecular weight of about 8750. Also suitable are polyoxyethylene stearate and palmitate. In the carrier beta lactose, sucrose, dextrose, sodium chloride, or sodium sulphate may form the water-soluble part and the balance may be starch with which methylcellulose, guar gum or purified wood cellulose may be mixed. Shaped preparations for nasal, urethral, vaginal and rectal application are prepared. As medicinal ingredients there can be incorporated: steroids, for example, estrone, testosterone, progesterone, hydrocortisone, prednisolone, 6-methyl prednisolone, and their therapeutically active derivatives; hypnotics and sedatives, for example phenobarbital, pentobarbital and amobarbital; antibiotics, for example, neomycin, bacitrocin, polymyxin, erythromycin, tyrothricin, gramicidin; diuretics, for example, aminophylline and theophylline; trichomonicides, for example, phenylmercuric acetate, sodium lauryl sulphate, oxyquinoline benzoate; antiseptics and bactericidal agents, for example, hexachlorophene, hexylresorcinol, nitrofurazone, myristyl g -picolinium chloride, sulfadiazine, phenol, secondary amyl tricresols; anaesthetics, for example, benzocaine, procaine, tetracaine; vasoconstrictors, for example, epinephrine, phenylephrine; analgesics, for example, caffeine and ergotamine tartrate, acetylsilicylic acid, acetophenetidin, N-acetyl-p-amino-phenol; narcotitizing medicaments, for example, morphine, dihydromorphinone, scopolamine and codeine.
GB15720/59A 1958-06-25 1959-05-07 Improvements in or relating to pharmaceutical preparations Expired GB887872A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US887872XA 1958-06-25 1958-06-25

Publications (1)

Publication Number Publication Date
GB887872A true GB887872A (en) 1962-01-24

Family

ID=22213459

Family Applications (1)

Application Number Title Priority Date Filing Date
GB15720/59A Expired GB887872A (en) 1958-06-25 1959-05-07 Improvements in or relating to pharmaceutical preparations

Country Status (1)

Country Link
GB (1) GB887872A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028589A2 (en) * 1999-10-15 2001-04-26 Rainer Rogasch Shaped body comprising an amphiphilic outer phase and a lipophilic inner phase
US10010612B2 (en) 2007-05-25 2018-07-03 Indivior Uk Limited Sustained delivery formulations of risperidone compounds
US10022367B2 (en) 2014-03-10 2018-07-17 Indivior Uk Limited Sustained-release buprenorphine solutions
US10058554B2 (en) 2005-09-30 2018-08-28 Indivior Uk Limited Sustained release small molecule drug formulation
US10172849B2 (en) 2010-06-08 2019-01-08 Indivior Uk Limited Compositions comprising buprenorphine
US10198218B2 (en) 2010-06-08 2019-02-05 Indivior Uk Limited Injectable flowable composition comprising buprenorphine

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028589A3 (en) * 1999-10-15 2002-04-11 Rainer Rogasch Shaped body comprising an amphiphilic outer phase and a lipophilic inner phase
US7541047B2 (en) * 1999-10-15 2009-06-02 Rainer Rogasch Method for production of shaped body for treating wounds in milk producing animals
WO2001028589A2 (en) * 1999-10-15 2001-04-26 Rainer Rogasch Shaped body comprising an amphiphilic outer phase and a lipophilic inner phase
US10058554B2 (en) 2005-09-30 2018-08-28 Indivior Uk Limited Sustained release small molecule drug formulation
US11110093B2 (en) 2005-09-30 2021-09-07 Indivior Uk Limited Sustained release small molecule drug formulation
US11013809B2 (en) 2007-05-25 2021-05-25 Indivior Uk Limited Sustained delivery formulations of risperidone compound
US10010612B2 (en) 2007-05-25 2018-07-03 Indivior Uk Limited Sustained delivery formulations of risperidone compounds
US11712475B2 (en) 2007-05-25 2023-08-01 Indivior Uk Limited Sustained delivery formulations of risperidone compound
US10376590B2 (en) 2007-05-25 2019-08-13 Indivior Uk Limited Sustained delivery formulations of risperidone compound
US10172849B2 (en) 2010-06-08 2019-01-08 Indivior Uk Limited Compositions comprising buprenorphine
US10558394B2 (en) 2010-06-08 2020-02-11 Indivior Uk Limited Injectable flowable composition comprising buprenorphine
US10592168B1 (en) 2010-06-08 2020-03-17 Indivior Uk Limited Injectable flowable composition comprising buprenorphine
US10198218B2 (en) 2010-06-08 2019-02-05 Indivior Uk Limited Injectable flowable composition comprising buprenorphine
US10517864B2 (en) 2014-03-10 2019-12-31 Indivior Uk Limited Sustained-release buprenorphine solutions
US10022367B2 (en) 2014-03-10 2018-07-17 Indivior Uk Limited Sustained-release buprenorphine solutions

Similar Documents

Publication Publication Date Title
DE3873410T2 (en) FORMULATION FOR ORAL DRUG DELIVERY AND METHOD FOR THE PRODUCTION THEREOF.
US4136162A (en) Medicament carriers in the form of film having active substance incorporated therein
AU731208B2 (en) New foam-forming pharmaceutical composition
CH625704A5 (en) Pharmaceutical composition in sheet form
US2698822A (en) Cardiac glycoside buccal composition
EP0303713B2 (en) Percutaneous absorption promoter and dermatologic preparation for external use
US2975099A (en) Polyethylene glycol suppository bases
US4948588A (en) Percutaneous absorption accelerator and preparation containing same
DE2432925C3 (en) Film-shaped medicinal products
JPS5620509A (en) Long-acting pharmaceutical preparation for nasal cavity use, and method for manufacturing the same
GB1446626A (en) Composition for sustained release of a medicament and method of using same
RO116766B1 (en) Hemorrhoidal gel composition
MXPA02004930A (en) Novel topical oestroprogestational compositions with systemic effect.
US4383986A (en) Hemorrhoidal compositions
KR20010057582A (en) Method of preparing a water soluble film
GB2163649A (en) Long-lasting adhesive antifungal suppositories
US3968245A (en) Sympathomimetic topical and percutaneous administration with halogenated promoters
GB887872A (en) Improvements in or relating to pharmaceutical preparations
AU614069B2 (en) Bioadhesive suppository pharmaceutical preparations
JP2540294B2 (en) Transdermal formulation
Tyler Oral contraception
GB1470355A (en) Pharmaceutical compositions
EP0162239B1 (en) Percutaneous absorption accelerator and preparation containing same
JPH0390029A (en) Danazol suppository
US3068145A (en) Topical pharmaceutical formulations containing n, n-dimethylacetamide as an anti-inflammatory ingredient